Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.52 USD
Change Today -0.09 / -3.45%
Volume 132.2K
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

amyris inc (AMRS) Key Developments

Amyris, Inc. and Squalan Natural Health B.V. Partner to Accelerate Development and Sales of Neossance Personal Care Products

Amyris, Inc. and Squalan Natural Health B.V. have entered into agreements for the production and marketing of Neossance Squalane-based personal care products. The partnership between Amyris and Squalan accelerates development and market penetration of skin care and personal care products containing Amyris's Neossance Squalane, which is produced from plant sugars. Under this new relationship, Squalan will market and sell Neossance-based products to retailers and consumers, primarily in the European Union. As part of the agreement, Amyris is investing in Squalan and will have an option to acquire an ownership stake in Squalan and the right to appoint a member of Squalan's board of directors. Squalan will continue to be managed by founders Leslie van der Meijden and Monique Hugen.

Amyris Seeks Acquisitions

Amyris, Inc. (NasdaqGS:AMRS) has filed a Shelf Registration in the amount of $200.00 million, Amyris use the net proceeds for working capital, capital expenditures, research and development expenditures, commercial expenditures, repayment of indebtedness, acquisitions of new technologies or businesses, and investments.

Amyris, Inc. announced delayed annual 10-K filing

On 03/16/2015, Amyris, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Amyris, Inc. and Genome Compiler Corp. Enters Collaboration Agreement to Commercialize DNA Construction Software Services for the Pharma and Biotech Industries

Amyris, Inc. and Genome Compiler Corp. have entered into a collaboration agreement to integrate Amyris's automated lab services with Genome Compiler's online design tools and e-commerce platform to enable users to design and order DNA or other biological products seamlessly. This integration will provide a comprehensive solution from design to delivery of integrated DNA design and construction service, which promises to be more automated, less expensive, and more sophisticated than current offerings. Customers will benefit from Genome Compiler's software tools and Amyris's rich libraries of verified genetic parts, DNA construction and editing methods.

Amyris, Inc. Presents at Morgan Stanley MLP/Diversified Natural Gas, Utilities and Clean Tech Conference, Mar-05-2015

Amyris, Inc. Presents at Morgan Stanley MLP/Diversified Natural Gas, Utilities and Clean Tech Conference, Mar-05-2015 . Venue: The St. Regis, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMRS:US $2.52 USD -0.09

AMRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
American Power Group Corp $0.23 USD 0.00
China Clean Energy Inc $0.05 USD 0.00
Gevo Inc $2.72 USD -0.10
Solazyme Inc $3.79 USD -0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation AMRS Industry Range
Price/Earnings 100.0x
Price/Sales 4.6x
Price/Book NM Not Meaningful
Price/Cash Flow 87.3x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMYRIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at